Edwards Lifesciences Corp - 8-K Filing
Edwards Lifesciences raises full-year 2026 guidance following Q3 revenue growth of 10.5% to $1.72 billion. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $EW
Read the full article at SEC EDGAR
Part of the story Swedish Orphan Biovitrum Reports Q3 Revenue Growth and Upgrades FY2026 Outlook (6 articles)